Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

Launched by MAHIDOL UNIVERSITY · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called olanzapine can prevent nausea and vomiting in patients receiving certain types of chemotherapy that are known to cause these side effects. The study will compare olanzapine to a placebo, which is a dummy treatment that doesn’t contain any active medication. The goal is to see if olanzapine can help patients feel better during their chemotherapy treatment.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of cancer, specifically if you are starting treatment with one of the following chemotherapy drugs: oxaliplatin, irinotecan, or carboplatin. Unfortunately, people who are pregnant, breastfeeding, or have certain medical conditions, like uncontrolled brain metastasis or allergies to olanzapine, cannot join. If you decide to participate, you will receive either olanzapine or the placebo for a short period, and you'll be monitored for how well it helps with nausea and vomiting. This study is currently recruiting participants, and it aims to improve the quality of life for those undergoing chemotherapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
• • age of \>18 years old
• Exclusion Criteria:
• • pregnancy or breast feeding
• • has emetic episode within 24 hours
• • gut obstruction
• • uncontrolled brain metastasis
• • allergy to or current use of olanzapine
• • concomittant moderate or high emetogenic chemotherapy on day 2-5
• • Total bilirubin \> 2 mg/dl or creatinine clearance \< 30 ml/min
• • unable to swallow drug